173 related articles for article (PubMed ID: 19132374)
1. Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.
Robey RW; Obrzut T; Shukla S; Polgar O; Macalou S; Bahr JC; Di Pietro A; Ambudkar SV; Bates SE
Cancer Chemother Pharmacol; 2009 Aug; 64(3):575-83. PubMed ID: 19132374
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
Chearwae W; Shukla S; Limtrakul P; Ambudkar SV
Mol Cancer Ther; 2006 Aug; 5(8):1995-2006. PubMed ID: 16928820
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
4. The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2.
Shukla S; Robey RW; Bates SE; Ambudkar SV
Biochemistry; 2006 Jul; 45(29):8940-51. PubMed ID: 16846237
[TBL] [Abstract][Full Text] [Related]
5. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
[TBL] [Abstract][Full Text] [Related]
6. The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.
Bhullar J; Natarajan K; Shukla S; Mathias TJ; Sadowska M; Ambudkar SV; Baer MR
PLoS One; 2013; 8(8):e71266. PubMed ID: 23967177
[TBL] [Abstract][Full Text] [Related]
7. OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.
Kuang YH; Patel JP; Sodani K; Wu CP; Liao LQ; Patel A; Tiwari AK; Dai CL; Chen X; Fu LW; Ambudkar SV; Korlipara VL; Chen ZS
Biochem Pharmacol; 2012 Sep; 84(6):766-74. PubMed ID: 22750060
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2.
Murakami M; Ohnuma S; Fukuda M; Chufan EE; Kudoh K; Kanehara K; Sugisawa N; Ishida M; Naitoh T; Shibata H; Iwabuchi Y; Ambudkar SV; Unno M
Drug Metab Dispos; 2017 Nov; 45(11):1166-1177. PubMed ID: 28904007
[TBL] [Abstract][Full Text] [Related]
9. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.
Zhang Y; Laterra J; Pomper MG
Neoplasia; 2009 Jan; 11(1):96-101. PubMed ID: 19107236
[TBL] [Abstract][Full Text] [Related]
10. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Shi Z; Tiwari AK; Shukla S; Robey RW; Singh S; Kim IW; Bates SE; Peng X; Abraham I; Ambudkar SV; Talele TT; Fu LW; Chen ZS
Cancer Res; 2011 Apr; 71(8):3029-41. PubMed ID: 21402712
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Shukla S; Robey RW; Bates SE; Ambudkar SV
Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
13. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
Komatani H; Kotani H; Hara Y; Nakagawa R; Matsumoto M; Arakawa H; Nishimura S
Cancer Res; 2001 Apr; 61(7):2827-32. PubMed ID: 11306452
[TBL] [Abstract][Full Text] [Related]
14. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
15. Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface.
Ozvegy-Laczka C; Várady G; Köblös G; Ujhelly O; Cervenak J; Schuetz JD; Sorrentino BP; Koomen GJ; Váradi A; Német K; Sarkadi B
J Biol Chem; 2005 Feb; 280(6):4219-27. PubMed ID: 15557326
[TBL] [Abstract][Full Text] [Related]
16. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.
Holland ML; Lau DT; Allen JD; Arnold JC
Br J Pharmacol; 2007 Nov; 152(5):815-24. PubMed ID: 17906686
[TBL] [Abstract][Full Text] [Related]
17. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
[TBL] [Abstract][Full Text] [Related]
18. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
[TBL] [Abstract][Full Text] [Related]
19. Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.
Zhang Y; Byun Y; Ren YR; Liu JO; Laterra J; Pomper MG
Cancer Res; 2009 Jul; 69(14):5867-75. PubMed ID: 19567678
[TBL] [Abstract][Full Text] [Related]
20. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
Zhang H; Kathawala RJ; Wang YJ; Zhang YK; Patel A; Shukla S; Robey RW; Talele TT; Ashby CR; Ambudkar SV; Bates SE; Fu LW; Chen ZS
Int J Biochem Cell Biol; 2014 Jun; 51():111-9. PubMed ID: 24726739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
